Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Grows By 225.2%

VolitionRX Limited (NYSEAMERICAN:VNRX) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 2,224,050 shares, a growth of 225.2% from the August 15th total of 683,892 shares. Approximately 17.5% of the company’s shares are short sold. Based on an average daily volume of 40,219,957 shares, the short-interest ratio is presently 0.1 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VNRX. Jane Street Group LLC purchased a new stake in shares of VolitionRX during the fourth quarter valued at approximately $28,000. Virtu Financial LLC increased its position in shares of VolitionRX by 166.6% during the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 67,848 shares in the last quarter. Squarepoint Ops LLC purchased a new position in VolitionRX in the 4th quarter worth approximately $34,000. Northwestern Mutual Wealth Management Co. purchased a new position in VolitionRX in the 2nd quarter worth approximately $52,000. Finally, Citadel Advisors LLC lifted its position in VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on VNRX shares. Maxim Group reissued a “buy” rating and set a $4.00 price objective on shares of VolitionRX in a research report on Thursday, June 18th. Benchmark reiterated a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.00.

VolitionRX Stock Performance

Shares of VolitionRX stock traded down $0.03 during midday trading on Friday, hitting $0.31. The company had a trading volume of 1,046,498 shares, compared to its average volume of 22,753,156. The company has a 50 day moving average of $0.75 and a 200 day moving average of $2.11. The stock has a market capitalization of $4.23 million, a P/E ratio of -0.08 and a beta of 1.10. VolitionRX has a 52-week low of $0.31 and a 52-week high of $14.80.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Thursday, August 13th. The medical research company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.41 million. Equities research analysts forecast that VolitionRX will post -2.36 EPS for the current year.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.